Crunch time for FDA user fees as reauthorization looks to hitch a ride on short-term spending bill
The lifeblood of the FDA’s drug reviews — the user fees that industry pays FDA for timely reviews of new and generic drugs over five-year periods …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
